Afsharzadeh Mahtab, Varshosaz Jaleh, Mirian Mina, Hasanzadeh Farshid
Novel Drug Delivery Systems Research Centre and Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, PO Box 81745-359, Isfahan, Iran.
Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Invest New Drugs. 2024 Feb;42(1):89-105. doi: 10.1007/s10637-023-01409-9. Epub 2023 Dec 21.
This study aimed to prepare SLC7A5 transporters targeted liposomes of Ribociclib (RB) by stear(o)yl conjugation of Phe, Asp, Glu amino acids to liposomes as targeting moieties. The liposomes were optimized for their formulations. Cell analysis on two cell lines of MCF-7 and NIH-3T3 were done including; cell viability test by MTT assay, cellular uptake, and cell cycle arrest by flow cytometry. The optimal liposomes showed the particle size of 123.6 ± 1.3 nm, drug loading efficiency and release efficiency of 83.87% ± 1.33% and 60.55% ± 0.46%, respectively. The RB loaded liposomes showed no hemolysis activity. Targeted liposomes increased cytotoxicity on MCF-7 cells more significantly than NIH-3T3 cells. Cell flow cytometry indicated that targeted liposomes uptake was superior to plain (non-targted) liposomes and free drug. Free drug and RB-loaded liposomes interrupted cell cycle in G1. However, amino acid-targeted liposomes arrested cells more than the free drug at this stage. Targeted liposomes reduced cell cycle with more interruption in the G2/M phase compared to the negative control.
本研究旨在通过将苯丙氨酸、天冬氨酸、谷氨酸氨基酸硬脂酰化作为靶向部分与脂质体偶联,制备靶向SLC7A5转运体的瑞博西尼(RB)脂质体。对脂质体的配方进行了优化。对MCF-7和NIH-3T3两种细胞系进行了细胞分析,包括:通过MTT法进行细胞活力测试、细胞摄取以及通过流式细胞术进行细胞周期阻滞分析。最佳脂质体的粒径为123.6±1.3nm,载药效率和释放效率分别为83.87%±1.33%和60.55%±0.46%。载有RB的脂质体无溶血活性。靶向脂质体对MCF-7细胞的细胞毒性比NIH-3T3细胞更显著。细胞流式细胞术表明,靶向脂质体的摄取优于普通(非靶向)脂质体和游离药物。游离药物和载有RB的脂质体在G1期阻断细胞周期。然而,在此阶段,氨基酸靶向脂质体比游离药物使更多细胞停滞。与阴性对照相比,靶向脂质体在G2/M期更多地中断细胞周期,从而缩短细胞周期。